Latanelb

Latanoprost, the active ingredient in Latanelb, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intraocular pressure and is used to treat open‑angle glaucoma and ocular hypertension in adults. GNH USA supplies Latanelb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanelb belongs to the prostaglandin analog class and is employed to manage conditions characterized by elevated intraocular pressure.

Open‑angle glaucoma: reduces intraocular pressure to prevent optic‑nerve damage. Ocular hypertension: lowers eye pressure to lower the risk of developing glaucoma. Secondary open‑angle glaucoma: helps control pressure when other causes are present.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash length and thickness - Darkening of the iris pigment - Eye irritation or foreign‑body sensation - Blurred vision - Dry eye or tearing

Serious or Rare Side Effects: - Uveitis or intraocular inflammation - Corneal edema or keratitis - Macular edema leading to visual disturbance - Severe allergic reaction (e.g., angio‑edema) - Persistent vision loss - Rapid, uncontrolled lowering of intraocular pressure (hypotony).

Before initiating therapy, clinicians should evaluate ocular health and monitor patients regularly.

Monitor intraocular pressure: schedule periodic eye‑pressure measurements. Assess for ocular infections: watch for signs of conjunctivitis or keratitis. Avoid use in active uveitis: contraindicated in inflamed eyes. Caution with corneal disorders: may exacerbate existing corneal disease. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, requiring careful management.

Major Interactions (Avoid): - Concomitant prostaglandin analogs: additive pressure‑lowering may cause hypotony. - Carbonic anhydrase inhibitors: increased risk of ocular irritation. - Ocular steroids: may diminish steroid efficacy and increase side‑effect risk.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intraocular pressure reduction. - Systemic NSAIDs: possible alteration of prostaglandin metabolism. - Anticholinergic eye drops: may reduce therapeutic response.